Skip to content
Study details
Enrolling now

PLX038 in Brain and Spinal Cord Tumors

National Cancer Institute (NCI)
NCT IDNCT06161519ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

120

Study length

about 9.8 years

Ages

18–120

Locations

1 site in MD

What this study is about

This trial is testing a treatment called PLX038 in people with certain types of brain or spinal cord tumors. The goal is to see if this drug can help these patients. Participants will have tests done, including imaging scans and blood work, before starting the treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take PLX038

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Determine overall survival (OS), Determine progression free survival (PFS), Longitudinally evaluate patient reported outcomes (PRO)

Body systems

Oncology